Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin degludec with insulin aspart in adults with type 1 diabetes
2020-002374-27Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetes mellitus type 1 (T1D) comparing Once-weekly insulin icodec + insulin aspart with Once-daily insulin degludec + insulin aspart (2 arms). Primary endpoint: Change in HbA1c. Started Jan 2021; status: completed.
02
Drugs
insulin icodecinsulin degludecinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2020-002374-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002374-27.